| Fumena (vorolanib) / Tyrogenex, Betta Pharma |
| Active, not recruiting | 3 | 390 | RoW | CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus | AnewPharma | Renal Cell Cancer Metastatic | 02/21 | 12/21 | | |
NCT04373369: Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 11 | US | Vorolanib, X-82, Atezolizumab, Tecentriq | Washington University School of Medicine, Xcovery Holdings, Inc. | Extensive-stage Small Cell Lung Cancer | 08/22 | 07/25 | | |
NCT06406673: A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 70 | RoW | Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib | Henan Cancer Hospital | Extensive Small Cell Lung Cancer | 08/24 | 12/24 | | |
NCT03583086: Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors |
|
|
| Active, not recruiting | 1/2 | 88 | US | Vorolanib, Nivolumab | Vanderbilt-Ingram Cancer Center, Bristol-Myers Squibb, Xcovery Holdings, Inc. | Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer | 02/24 | 07/25 | | |
ChiCTR-IID-17013889: Phase I clinical trial of the safety, tolerability, pharmacokinetics and initial efficacy of CM082 in the treatment of wet age-related macular degeneration (wAMD) |
|
|
| Completed | 1 | 108 | | 25mg dose ;50mg dose ;75mg dose ;100mg dose | Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University, Kananji Medical Technology (Shanghai) Co., Ltd. | wet age-related macular degeneration | | | | |
NCT03792958: Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 19 | RoW | CM082, X-82 | AnewPharma, Shanghai East Hospital | Advanced Malignant Solid Tumors | 06/23 | 06/23 | | |
